Physician profile
David Rosania
NPI 1346281888
$8,837.25
in general payments reported to CMS, 2019-2025
48 companies · $60.99 in 2025
The $60.99 reported for 2025 was less than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,001 · 2020: $2,229 · 2021: $1,749 · 2022: $1,230 · 2023: $1,296 · 2024: $271 · 2025: $60.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,628.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $2,377.87 | 2019-2021 | |
| Abbvie INC. | $906.29 | 2022-2023 | Ubrelvy, Qulipta, Botox |
| Horizon Therapeutics Plc | $756.79 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $642.06 | 2019-2025 | Nucynta, Belbuca |
| Medtronic, INC. | $524.58 | 2021-2022 | |
| Medtronic USA, INC. | $377.72 | 2019-2020 | |
| Si-Bone, INC. | $339.12 | 2019-2021 | |
| Foundation Fusion Solutions, LLC | $306.71 | 2021-2023 | |
| Allergan, INC. | $259.94 | 2019-2022 | |
| Nalu Medical, INC. | $259.15 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $255.48 | 2022-2025 | Relistor |
| Lilly USA, LLC | $184.46 | 2021-2023 | Emgality, Reyvow |
| Boston Scientific Corporation | $181.44 | 2021-2024 | |
| Sentynl Therapeutics, INC. | $122.70 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $88.27 | 2022 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rosania listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.